Fluxion Biosciences signs distribution agreement with DI Biotech and Novel Science

Fluxion Biosciences announced today that it has expanded its sales and service network into Asia. The company signed a distribution agreement for its BioFlux™ line with Korea-based DI Biotech. A second agreement with Novel Science covers sales of both the BioFlux and IonFlux™ platforms in Japan. Fluxion has also sold its first BioFlux 1000 system into China. The China Academy of Chinese Medical Science will initially use this system for research on inhibition of thrombus formation on endothelial cells.

Fluxion’s BioFlux instruments enable live cell image analysis for physiologically-relevant shear flow assays in a standard well-plate format. Ideal applications include research in cell and platelet adhesion, cancer biology, stem cells and microbial biofilms. The IonFlux line combines Fluxion’s proprietary microfluidic technology with integrated electronics to automate the traditional patch clamp assay, the “gold standard” in ion channel research. Ideal drug discovery applications include primary/secondary screening, lead optimization and toxicology screening.

DI Biotech Ltd. is headquartered in Seoul, Korea, and has a branch office in Daejeon City. DI Biotech has been a market leader and pioneer in Korea's Life Science market. The company works closely with its customers, with a focus on genomics, molecular biology, peptide synthesis and cell imaging. S. E. Kim, CEO and President at DI Biotech comments, “Awareness of the importance of shear stress is increasing among researchers. The static biological method will move toward more dynamic assays using shear stress control to get closer in vivo data. I am delighted to introduce technology from Fluxion Bioscience to the Korean market and to our customers in cell biology research.”

Novel, Inc. serves a range of life science research customers, providing both instruments and consumable reagents. The company specializes in tools for immune research. Hiraoka Kazuhiko CEO, commented, “At Novel Science, we contribute to biotechnology advancement by importing and supplying leading edge cytometric research tools. The Fluxion tools will help us improve our range of offerings for our customers in cellular research.”

“We are confident that these two leading distributors will help us expand our research and drug discovery systems into the growing Asian markets,” said Mark Atlas, sales director of Fluxion.

Source:

 Fluxion Biosciences

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Fluxion Biosciences. (2019, June 19). Fluxion Biosciences signs distribution agreement with DI Biotech and Novel Science. News-Medical. Retrieved on January 19, 2020 from https://www.news-medical.net/news/20091204/Fluxion-Biosciences-signs-distribution-agreement-with-DI-Biotech-and-Novel-Science.aspx.

  • MLA

    Fluxion Biosciences. "Fluxion Biosciences signs distribution agreement with DI Biotech and Novel Science". News-Medical. 19 January 2020. <https://www.news-medical.net/news/20091204/Fluxion-Biosciences-signs-distribution-agreement-with-DI-Biotech-and-Novel-Science.aspx>.

  • Chicago

    Fluxion Biosciences. "Fluxion Biosciences signs distribution agreement with DI Biotech and Novel Science". News-Medical. https://www.news-medical.net/news/20091204/Fluxion-Biosciences-signs-distribution-agreement-with-DI-Biotech-and-Novel-Science.aspx. (accessed January 19, 2020).

  • Harvard

    Fluxion Biosciences. 2019. Fluxion Biosciences signs distribution agreement with DI Biotech and Novel Science. News-Medical, viewed 19 January 2020, https://www.news-medical.net/news/20091204/Fluxion-Biosciences-signs-distribution-agreement-with-DI-Biotech-and-Novel-Science.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
Fluxion Biosciences announces release of IsoFlux Rare Cell Enrichment Kit